Engineered GM-CSF polarizes protumorigenic tumor-associated macrophages to an antitumorigenic phenotype and potently synergizes with IL-12 immunotherapy

Background The use of immune checkpoint inhibitors (CPIs) has become a dominant regimen in modern cancer therapy, however immune resistance induced by tumor-associated macrophages (TAMs) with immune suppressive and evasion properties limits responses. Therefore, the rational design of immune modulat...

Full description

Saved in:
Bibliographic Details
Main Authors: Yue Wang, Kevin Chang, Aslan Mansurov, Jun Ishihara, Seounghun Kang, Trevin Kurtanich, Hye Rin Chun, Anna J Slezak, Lisa R Volpatti, Thomas Wang, Aaron T Alpar, Kirsten C Refvik, O Isabella Hansen, Gustavo J Borjas, Brendan T K Berg, Ha-Na Shim, Kevin T Hultgren, Suzana Gomes, Ani Solanki, Melody A Swartz, Jeffrey A Hubbell
Format: Article
Language:English
Published: BMJ Publishing Group 2024-12-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/12/12/e009541.full
Tags: Add Tag
No Tags, Be the first to tag this record!